Onkos Surgical this week announced it signed a multi-year agreement with Integrum to expand to market for Integrum’s OPRA Implant System.
The collaboration is expected to commence immediately and will focus on expanding the U.S. market for Integrum’s Osseoanchored Prostheses for the Rehabilitation of Amputees (OPRA) Implant System.
“We are delighted to partner with Dr. Brånemark and Integrum, global experts and leading pioneers in the field of osseointegration,” Onkos Surgical co-founder and CEO Patrick Treacy said in a news release. “Integrum continues to revolutionize the field of bone-anchored prosthetics and, given our focus in limb salvage, the OPRA technology is complementary to our portfolio strategy. The combined expertise of both companies will provide surgeons with greater access to advanced bone-anchored prosthetics and provide patients with meaningful reconstructive options.”
The OPRA Implant System is a bone-anchored prosthetic solution that is available in the U.S. It features an anchorage element and a skin penetrating device and is surgically inserted into the femur. After several months of healing, the abutment is connected to the fixture. The prosthetic leg can then be attached to the abutment through the OPRA Axor connection and safety device.
“We are pleased to partner with a world-class company like Onkos Surgical for the benefit of the U.S. market. I’m convinced that together Integrum and Onkos can accelerate the adoption of the OPRA technology, providing more options for amputees wanting to take advantage of this remarkable technology,” Integrum CEO Maria Lopez said.